We are live on ! Find out more
KAPA

Kairos Pharma
KAPA

8 hedge funds and large institutions have $1.46M invested in Kairos Pharma in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

137% more capital invested

Capital invested by funds: $618K → $1.46M (+$845K)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

60% more funds holding

Funds holding: 5 → 8 (+3)

1.19% more ownership

Funds ownership: 0.45% → 1.64% (+1.2%)

Holders
8
Holders Change
+3
Holders Change %
+60%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.8M
2
SRL
Scientech Research LLC
New Jersey
+$61.7K
3
ACA
Aptus Capital Advisors
Alabama
+$56.7K
4
SFG
SevenBridge Financial Group
Pennsylvania
+$56.7K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$26.2K

Top Sellers

Rank Fund Capital Flow
1
UB
UMB Bank
Missouri
-$564K
2
VF
Virtu Financial
New York
-$21K
3
UBS Group
UBS Group
Switzerland
-$10.3K

KAPA Hedge Fund Activity: Q1 2025 in Review

8 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Kairos Pharma (KAPA) for Q1 2025, worth a combined $1.46M — up 137% from $618K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new KAPA positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.8M. The largest seller was UMB Bank, exiting entirely with an estimated $564K sold.

  • 8 institutional investors held Kairos Pharma (KAPA) as of Q1 2025, up from 5 in Q4 2024.
  • Funds reported $1.46M of Kairos Pharma stock for Q1 2025, up 137% quarter-over-quarter.
  • 5 funds opened new Kairos Pharma positions in Q1 2025 and 2 closed out, a net change of +3 holders.
  • The largest Kairos Pharma buyer in Q1 2025 was Armistice Capital, an estimated $1.8M added.
  • The largest Kairos Pharma seller in Q1 2025 was UMB Bank, an estimated $564K sold.

Based on aggregated 13F filings for Q1 2025.